Cowen & Co. Maintains Their Buy Rating on CryoPort Inc (CYRX)

Cowen & Co. analyst Jason Seidl maintained a Buy rating on CryoPort Inc (CYRX) today and set a price target of $16. The company’s shares closed yesterday at $11.56.

According to, Seidl is a top 100 analyst with an average return of 15.9% and a 71.5% success rate. Seidl covers the Services sector, focusing on stocks such as Covenant Transportation Group, Expeditors International, and Echo Global Logistics.

CryoPort Inc has an analyst consensus of Moderate Buy, with a price target consensus of $19.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.88 and a one-year low of $6.02. Currently, CryoPort Inc has an average volume of 268.7K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2018, Richard J. Berman, a Director at CYRX sold 10,000 shares for a total of $140,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Lake Forest, CA.